We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company
News

NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company

NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company
News

NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Pharmaceutical Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NanoMaterials Technology ("NMT") has announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.

As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.

"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.

NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").

"It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry," says Dr. Yun.

Advertisement